Comparative Pharmacology
Head-to-head clinical analysis: CLEOCIN T versus EVOCLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLEOCIN T versus EVOCLIN.
CLEOCIN T vs EVOCLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, suppressing peptide bond formation. It exhibits bacteriostatic activity against susceptible organisms.
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S subunit of the ribosome, blocking peptide bond formation.
Apply a thin film of 1% solution or gel twice daily to affected skin areas.
EVOCLIN (clindamycin phosphate) foam 1%: Apply once daily to affected area(s) of the face, shoulders, chest, and back.
None Documented
None Documented
The terminal elimination half-life in adults with normal renal and hepatic function is approximately 2-3 hours. In severe hepatic impairment, half-life may increase to 5-6 hours. No significant alteration in renal impairment.
Terminal elimination half-life is approximately 15 hours (range 10-25 hours) following topical application, allowing for twice-daily dosing.
Clindamycin is primarily eliminated via hepatic metabolism and biliary excretion. Approximately 10% of the active drug is excreted renally, with the remainder as inactive metabolites in feces (biliary/fecal route).
Primarily hepatic metabolism; renal excretion of unchanged drug accounts for approximately 10% of elimination. Biliary/fecal excretion accounts for <2%.
Category C
Category C
Topical Antibiotic
Topical Antibiotic